Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Altering The Insulin Resistance System

This article was originally published in Start Up

Executive Summary

With the US deeply mired in an obesity epidemic, a growing aging population throughout the developed world, and rising rates of obesity, the market for therapeutic agents for metabolic disorders and especially type 2 diabetes will continue to grow. Little wonder that many emerging companies are pursuing innovative metabolic, obesity, and type 2 diabetes programs to supplement those of Big Pharma. We profile four of them in this issue: Catabasis Pharmaceuticals, Limerick BioPharma, Marcadia Biotech and Rhythm Pharmaceuticals.
Advertisement

Related Content

Catabasis Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc.
Limerick BioPharma Inc.
Marcadia Biotech Inc.
Start-Up Previews (06/2010)
Catabasis Pharmaceuticals Inc.
Limerick BioPharma Inc.
IL-1 Beta Beckons In Type 2 Diabetes and Potentially, Cardiovascular Disease
IL-1 Beta Beckons In Type 2 Diabetes and Potentially, Cardiovascular Disease
Marrying Glucagon with GLP-1 to Treat Obesity

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC091984

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel